Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

http://www.wikidata.org/entity/Q37478401

about

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly Impact of pneumococcal conjugate vaccination: a retrospective study of hospitalization for pneumonia in North-East Italy Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies.A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?Costs associated with community acquired pneumonia in France.Evaluating the costs and benefits of pneumococcal vaccination in adults.Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy.Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions.The full benefits of adult pneumococcal vaccination: A systematic review.Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.

P2860

Q26999313-EA987D99-BB5E-4AF5-B2C0-1CE4808DED8A Q28075109-20B5CC84-B71C-4F9F-BA66-4087C2EB83AB Q33675229-2CFB6ABC-5526-49C2-A5F7-93BC57564B68 Q34290690-519379E0-4996-491A-BA22-133A91888B7C Q34402444-856D0EB5-938B-4465-8D4E-D247AA79CD99 Q34798448-1F0B7494-1373-4478-A251-4D9C57B68E2B Q36446832-3A9666F9-1CCB-4735-98BF-32F29B6A5802 Q36580689-1130C1E5-D5CD-4971-A9A2-E33BC251316D Q36977904-851AEBB1-F333-4007-8E71-F811B9A75132 Q37197088-3B90785F-BCCC-442F-8640-A104383E0C7D Q38167294-6C8484EE-D9D8-4785-A750-352DE22E5BF1 Q38620718-484A0C71-E863-4BEA-AF20-D144865F0C87 Q38762048-338E96A9-5FCC-4A95-B9B7-2B909D5212FF Q38966828-605A1BC4-8477-415B-A1FB-87F69AEE1C0A Q39124135-75112925-A188-45F3-A42B-49CD09AAB4DB Q46212111-B8C12829-487F-4121-A34B-D141FB64B7ED Q47098784-DA4923E7-67FD-4EDB-B9B3-F281011091AC Q48504278-73054A71-043F-460B-8320-54F68C11486A Q55277513-34B7BCF3-F640-47A2-A910-5586E3846CE3

P2860

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

http://www.wikidata.org/entity/Q37478401

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@en

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@nl

type

label

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@en

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@nl

prefLabel

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@en

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@nl

P1433

Q37478401-4B2732A4-19F2-42AD-BA81-68F4083F81B9

P1476

Q37478401-729C1880-E964-41E7-B3DA-49C242ACE3EA

P2093

Q37478401-0C0B14D6-87CE-46C4-9348-30F66D65F4D6

Q37478401-17770953-737D-461B-A7B6-C502C4A0BDE9

Q37478401-574BA075-7DF5-4FB0-B594-26B3C9DCA733

Q37478401-DB97AF04-B2C4-4363-A7AD-A89ADD07D58A

P2860

Q37478401-182CE76F-AD4B-45A9-A69D-E90F6011AA18

Q37478401-25FF7C70-5E29-4A45-B312-C9BB2CBD8D37

Q37478401-2A912E21-B838-42C9-AD4F-CE43DC303BD5

Q37478401-3B9FFC1D-2A80-4F4E-959A-A7A89BB1D3FB

Q37478401-3FEAF893-B6ED-4A11-BE48-8DE6C99100FB

Q37478401-606728B8-55C3-4149-8AA4-502A9962998C

Q37478401-8BE25384-7CF1-4BF5-B155-E20BAEA7167C

Q37478401-9055B780-29E5-4165-8FF3-70EBACB8B0EE

Q37478401-9167B650-251F-4598-88BC-F09A87CC50F0

Q37478401-9B8B0EFA-237F-48BE-9AFE-6D2126AB1A6E

P304

Q37478401-6FC25B5C-76D5-4919-9C36-3DBA58593727

P31

Q37478401-AB63D640-9277-4733-B2B4-1D53C36CB0F1

P356

Q37478401-66E6F1D0-276B-47B7-98C7-D55B37797E7F

P433

Q37478401-607913F7-9056-4A50-934D-71796AAE9145

P478

Q37478401-806D6041-84EB-44F4-AF6E-F6BDAF4FDD98

P50

Q37478401-112FB387-8696-4B59-9B4C-1BC3363510D6

Q37478401-848615CB-BD9D-4824-9B16-CCEB09AFF425

P577

Q37478401-89DE92AF-FC33-47F0-BBF6-9804FB3D767F

P5875

Q37478401-04D11E20-096C-420F-87CC-1FF78AD18C9A

P698

Q37478401-D05EDFFC-EAEC-4BB3-A706-6958B1B94B8E

P921

Q37478401-2E4B694C-7960-4DAA-9EB0-0C7FD5EBCEA3

P932

Q37478401-EEA32C76-FCF0-45E2-80B1-3DE09C62EFDD

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

@en

P2093

Angela Bechini

http://www.w3.org/2001/XMLSchema#string

Emila Tiscione

http://www.w3.org/2001/XMLSchema#string

Paolo Bonanni

http://www.w3.org/2001/XMLSchema#string

Sara Boccalini

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines for preventing pneumococcal infection in adults

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

The antineutrophil cytoplasmic antibody-associated vasculitides.

Efficacy of pneumococcal vaccination in adults: a meta-analysis.

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells

Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern.

Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.

P304

699-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.23268

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Gasparini

P577

2013-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234083978

http://www.w3.org/2001/XMLSchema#string

P698

23295824

http://www.w3.org/2001/XMLSchema#string

P921

P932

3891731

http://www.w3.org/2001/XMLSchema#string